BIIB100, developed by Biogen, is currently in Phase 1 clinical trials for the treatment of amyotrophic lateral sclerosis (ALS). The market for ALS therapies is growing, driven by increasing awareness and diagnosis rates, alongside a limited number of effective treatment options. The competitive landscape includes established therapies like riluzole and edaravone, but there remains a significant unmet need for novel treatments that can improve patient outcomes. Successful completion of this trial could position Biogen favorably in the ALS market, potentially leading to partnerships or acquisition interest from larger pharmaceutical companies. Diligence should focus on the safety and tolerability profile of BIIB100, as well as its pharmacokinetic characteristics, which will be critical for future development stages.